Prolongation of islet xenograft survival with combined treatment of 15-deoxyspergualin or cyclosporine and anti-CD4 monoclonal antibody.
Lu
X
X
Preclinical Research, Sandoz Pharma Ltd, Basel, Switzerland.
Borel
J F
JF
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D015704:CD4 Antigens / Q000276:immunology*; D002478:Cells, Cultured; D003131:Combined Modality Therapy; D006224:Cricetinae; D016572:Cyclosporine / Q000627:therapeutic use*; D003921:Diabetes Mellitus, Experimental / Q000628:therapy; D006085:Graft Survival / Q000187:drug effects / Q000276:immunology*; D006146:Guanidines / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007515:Islets of Langerhans / Q000166:cytology; D016381:Islets of Langerhans Transplantation / Q000276:immunology*; D008647:Mesocricetus; D051379:Mice; D008808:Mice, Inbred CBA; D014183:Transplantation, Heterologous / Q000276:immunology*
D000911:Antibodies, Monoclonal; D015704:CD4 Antigens; D006146:Guanidines; D007166:Immunosuppressive Agents; D016572:Cyclosporine; C037258:gusperimus